Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Methylphenidate, Rivastigmine or Haloperidol in Hypoactive Delirium in Intensive Care Patients
This study has been terminated.
( Inclusion rate too low due to a lack of eligible patients and difficulties obtaining informed consent. )
Study NCT00599287 Information provided by UMC Utrecht
First Received: January 10, 2008 Last Updated: May 27, 2008
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Delirium
Additional conditions recognized in this trial
Hypokinesia
More general conditions related to this trial
Confusion
Delirium, Dementia, Amnestic, Cognitive Disorders
Dyskinesias
Mental Disorders
Nervous System Diseases
Neurobehavioral Manifestations
Neurologic Manifestations
Signs and Symptoms
Interventions listed in this trial
Haloperidol
Methylphenidate
Rivastigmine
No intervention
Additional drug interventions recognized in this trial
Haloperidol decanoate
More general drug interventions related to this trial
Anti-Dyskinesia Agents
Antiemetics
Antipsychotic Agents
Autonomic Agents
Central Nervous System Agents
Central Nervous System Depressants
Central Nervous System Stimulants
Cholinergic Agents
Cholinesterase Inhibitors
Dopamine Agents
Dopamine Antagonists
Dopamine Uptake Inhibitors
Enzyme Inhibitors
Gastrointestinal Agents
Molecular Mechanisms of Pharmacological Action
Neuroprotective Agents
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Psychotropic Drugs
Therapeutic Uses
Tranquilizing Agents
Sponsors listed in this trial
UMC Utrecht
Back to top of Main Content
